Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-generation Antipsychotics in a Naturalistic Setting
NCT00932529Phase 4Completed
- Sponsor
- University of Bergen
- Start
- Feb 2003
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olanzapine, quetiapine, risperidone and ziprasidone in psychosis (4 arms), sponsored by University of Bergen. Primary endpoint: Positive and Negative Syndrome Scale total score reduction at 24 months. Started Feb 2003; status: completed.
02
Drugs
olanzapinequetiapinerisperidoneziprasidone
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT00932529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932529.